Breakthrough pain in cancer

被引:0
作者
Hilgier, Maciej [1 ]
机构
[1] Instut Marii Sklodowskiej Curie, Zaklad Medycyny Paliatywnej Centrum Onkologii, Oddzial Medycyny Paliatywnej & Badania Bolu, Warsaw, Poland
来源
WSPOTCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2007年 / 11卷 / 05期
关键词
cancer pain; breakthrough pain; breakthrough pain management;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breakthrough pain is defined brief flare up of severe pain that occurs even while the patient is regularly taking. pain meducation. Breakthrough pain is relatively common among cancer patients (affects over 50% of patients), particularly those with moderate to severe background pain. Breakthrough pain is one of the most difficult pain syndromes to treat. Breakthrough cancer pain can result from the cancer or cancer treatment, or it may occur during certain activity (e.g. walking, dressing, coughing). it also can occur unexpecte dly, without a preceding incident or clear cause. Persistent and breakthrough pain are distinct components of cancer pain and require separate management. Breakthrough pain is treated with a supplemental short-acting opioid used "as needed" (oral transmucosal fentanyl being the most interesting). Increasing the dose of around-the clock medication to cover ail episodes of breakthrough pain is one option, but often leads to over-sedation. One must consider also paracetamol and NSAIDs as rescue medication. Although breakthrough pain is usually managed with supplemental analgesic medication, other means of treatment should be considered such as primary antineoplstic therapies, orthotic devices, neural blocks and thermolesions, etc.
引用
收藏
页码:276 / 282
页数:7
相关论文
共 41 条
  • [1] BENNETT D, 2005, PHARMACOL THERAPEUT, V30, P296
  • [2] Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey
    Caraceni, A
    Martini, C
    Zecca, E
    Portenoy, RK
    [J]. PALLIATIVE MEDICINE, 2004, 18 (03) : 177 - 183
  • [3] An international survey of cancer pain characteristics and syndromes
    Caraceni, A
    Portenoy, RK
    [J]. PAIN, 1999, 82 (03) : 263 - 274
  • [4] Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study
    Carr, DB
    Goudas, LC
    Denman, WT
    Brookoff, D
    Staats, PS
    Brennen, L
    Green, G
    Albin, R
    Hamilton, D
    Rogers, MC
    Firestone, L
    Lavin, PT
    Mermelstein, F
    [J]. PAIN, 2004, 108 (1-2) : 17 - 27
  • [5] Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain
    Christie, JM
    Simmonds, M
    Patt, R
    Coluzzi, P
    Busch, MA
    Nordbrock, E
    Portenoy, RK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3238 - 3245
  • [6] Coluzzi P H, 1997, Semin Oncol, V24, pS16
  • [7] Breakthrough cancer pain:: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®)
    Coluzzi, PH
    Schwartzberg, L
    Conroy, JD
    Charapata, S
    Gay, M
    Busch, MA
    Chavez, J
    Ashley, J
    Lebo, D
    McCracken, M
    Portenoy, RK
    [J]. PAIN, 2001, 91 (1-2) : 123 - 130
  • [8] Bisphosphonates for controlling pain from metastatic bone disease
    Diener, KM
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (16) : 1917 - 1927
  • [9] *EXP COMM MAN SEV, 1984, CANC PAIN HLTH WELF
  • [10] A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain
    Fortner, BV
    Okon, TA
    Portenoy, RK
    [J]. JOURNAL OF PAIN, 2002, 3 (01) : 38 - 44